Stimation of Antiphospholipid and Anticardiolipin Antibodies in Sudanese Women with Recurrent Miscarriage in Khartoum State

Abstract

miscarriage is the occurrence of pregnancy loss before 20 weeks of gestation. Its divided into sporadic miscarriage which is most common complication of early pregnancy and recurrent miscarriage which is three consecutive pregnancy loss prior to 20 weeks from last menstrual period. Antiphospholipid Antibodies (APAs) are one of the causes responsible for pregnancy loss. The aim of study is to measure the levels of antiphospholipid and anticardiolipin antibodies (APL) among women with miscarriage. his was cross sectional study carried out at Khartoum State, during the period from January to march 2021. Fifty women with miscarriage were participated in this study as case group and compared to other 25 healthy participants as control group. Data was collected through written questionnaire, then specimen of 2ml of venous blood was drawn from each participant and placed in plain container , and tested for antiphospholipid (APL) )IgM\IgG) antibodies and anticadiolipn antibodies (ACL) (IgM/IgG) using ELISA assay, Results were analyzed by SPSS (Statistical Package of Social Science version 25). the results showed that the mean level of antiphospholipid IgM and anticardiolipin antibodies (IgM and IgG) showed significant increase in case group (4.54 , 8.84 , 6.11) when compared to control group(3.05, 2.9, 2.77) with (p. value= 0.016, 0.001, 0.005 respectively), while the mean level of IgG antiphospholipid show no significant difference between case and control group (3.90 versus 3.05 with p value= 0.217). Additionally, The study showed that there was no relationship between the disease and family history. The study showed that Those who were in age group 30-39 years had the significance high level of antiphospholipid and anticardiolipin antibodies compared to other group. This study concludes that there was significant increase in the mean level of antiphospholipid IgM and anticardiolipin antibodies (IgM and IgG) in case group when compared to control group.